Ruben A. Mesa, MD, discusses the JAK2 inhibitor pacritinib, which led to better symptom control and improved cytopenias in patients with myelofibrosis. Read more about PERSIST-1 here.
PERSIST-1: Pacritinib Shakes Up the Current Myelofibrosis Treatment Landscape
Recent Articles
States Reject $18 Billion Opioid Settlement
Attorneys general for 21 states as well as Puerto Rico and the District of Columbia rejected an $18 billion offer from McKesson, AmerisourceBergen, and...
FDA Braces for Shortages Due to Coronavirus
As the COVID-19 (coronavirus) outbreak continues to spread, the FDA is preparing for drug and medical supply shortages.
The agency has temporarily halted all plant...
Top-Earning Nonprofit Hospitals Provide Less Charity Care
Nonprofit hospitals with the highest net incomes tend to allocate the smallest proportion of their earnings to caring for uninsured and low-income patients, according...
U.S. Medical Schools Push to Recruit More LGBTQ Students
Backed by research that suggests patients receive better care when treated by clinicians more like them, medical schools in the U.S. are pushing for...
HHS Releases Recommendations to Reduce EHR Administrative Burden
The U.S. Department of Health and Human Services (HHS) has released their “Strategy on Reducing Regulatory and Administrative Burden Relating to the Use of...
Current Issue
February 2020, Volume 6, Issue 3
This issue examines the high price of treating hemophilia, asks whether CAR T-cell therapies are worth the cost, and more.
